Bromocriptine and imipramine in endogenous depression. A double-blind controlled trial in out-patients
by
Waehrens J, Gerlach J
J Affect Disord 1981 Jun; 3(2):193-202

ABSTRACT

Among 33 out-patients with endogenous depression, 16 were treated with bromocriptine (10-60 mg/day, mean 34) and 17 with imipramine (75-250 mg/day, mean 143). The total score on the Hamilton Rating Scale decreased during 6-week treatment from 19.9 to 7.8 in the bromocriptine group (P less than 0.001) and from 20.1 to 6.1 in the imipramine group (P less than 0.001). There was no significant difference between the two groups. The main side-effects were for bromocriptine: nausea, dizziness, and headache; for imipramine; dryness of mouth, dizziness, and sweating. This study suggests an antidepressant effect of bromocriptine although, due to the possibility of Type II error, it may not necessarily be equal to that of imipramine.

Options
Roxindole
Selegiline
Amineptine
Imipramine
Pramipexole
Nomifensine
Bromocriptine
Methylphenidate
Bromocriptine and cats
Bromocriptine in psychiatry
Dopaminergics and depression
Bromocriptine for nicotine addicts

Refs
HOME
HedWeb
Cocaine.org
Future Opioids
BLTC Research
Superhappiness?
Paradise-Engineering
The Abolitionist Project
The Hedonistic Imperative
MDMA: Utopian Pharmacology

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family